UNSPSC 51101620: Iodoquinol

This classification denotes an antiprotozoal agent with the molecular formula C9H5I2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63W7IE88K8, chemically known as 5,7-diodo-8-quinolinol but generally known as diiodohydroxyquinoline, which bears US NIH Compound Identifier 3728. European Medicines Agency schedules Diiodohydroxyquinoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07142MIG. The term DIIODOHYDROXYQUINOLINE is an International Non-Proprietary Name.

World Health Organization schedules diiodohydroxyquinoline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, IODOQUINOL remains the US FDA Preferred Term for this commodity. Iodoquinol bears US NLM identifiers UMLS ID C0012341 and NCI Concept Code C76008. SMILES: IC1C2C(NCCC2)C(O)C(I)C1.

UNSPSC 51101620 Iodoquinol, a Commodity code, shows limited alignment between its nominal scope and recent state and local procurement activity. The code nominally classifies a specific antiprotozoal pharmaceutical, yet recent opportunities posted under this code actually solicit naloxone, safe drug deactivation systems, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals with OTC products—none of which are iodoquinol. State and local buyers using this code classification appear to be health departments, public safety agencies, and cooperative purchasing alliances seeking pharmaceutical products, medical consumables, and emergency-response supplies through competitive bidding and RFP vehicles. The opportunities reflect procurement for community health initiatives, fire department rescue operations, and statewide pharmacy benefit programs rather than purchases specific to iodoquinol treatment.

Recent solicitations span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida (IFB 60459723LAS, due Jul 26, 2026) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission issued an RFI (HHS0017013, due Apr 3, 2026) to gather vendor capabilities for a direct-to-manufacturer pharmacy program; the City of Tampa posted an IFB (26P00145, due Mar 13, 2026) for 169 line items of medical and first aid supplies for its Fire Department Rescue Division, with an estimated contract value of $700,000 and a 5% bid discount for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due Mar 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The code shows no clear concentration among repeat buyers and exhibits mismatch between its stated scope and actual procurement activity across these jurisdictions.